Indications

• Hyperlipidemia (see Hyperlipidemia)

---

Pharmacology

• Mechanism: HMG-CoA Reductase Inhibitor (see HMG-CoA Reductase Inhibitors)

---

Administration

• PO:

---

Adverse Effects

Gastrointestinal Adverse Effects

Asymptomatic Elevation of Hepatic Transaminases (Isolated Transaminitis) (see Drug-Induced Hepatotoxicity)

• xxxx

Neurologic Adverse Effects

Exacerbation of Myasthenia Gravis (see Myasthenia Gravis)

• Physiology: class effect (these drugs have a clear effect on Myasthenia Gravis)

Pulmonary Adverse Effects

Interstitial Pneumonitis (see Interstitial Lung Disease)

• xxx

Organizing Pneumonia (see Cryptogenic Organizing Pneumonia)

• xxxx

Rheumatologic Adverse Effects

ANCA-Positive Vasculitis (see Anti-Neutrophil Cytoplasmic Antibody)

• Epidemiology: case reports

Positive Anti-Nuclear Antibody (ANA)/Drug-Induced Lupus (see Systemic Lupus Erythematosus)

• Epidemiology: case reports

Rhabdomyolysis (see Rhabdomyolysis)

• Epidemiology
• Physiology: class effect

Other Adverse Effects

• xxx

---

References

• Atorvastatin-induced reversible positive antinuclear antibodies. The American journal of medicine 2002;112;329-30 2002
• A case of interstitial lung disease with atorvastatin (Tahor) and a review of the literature about these effects observed under statins. Thérapie 2006 Jan-Feb;61;57-67 2006 Jan-Feb
• Statins and interstitial lung disease: a systematic review of the literature and of food and drug administration adverse event reports. Chest 2008;134;824-30 2008
• A case of ANCA-associated systemic vasculitis induced by atorvastatin. Clinical rheumatology 2008;27 Suppl 2;S75-7 2008
• Acute fibrinous and organising pneumonia: a case report and review of the literature. Journal of medical case reports 2009;3;74 2009
• Side effects of the HMG-CoA reductase inhibitors (statins). Lupus erythematosus induced by Atorvastatin therapy. Przegla̧d lekarski 2011;68;495-8 2011